Drugs / RAD101
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06777433 | Dec 2024 → Apr 2026 overdue | metastatic malignant neoplasm in the brain | Radiopharm Theranostics, Ltd | Active not recruiting | Met primary |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2026-07-23 | Radiopharm Theranostics, Ltd | Results Radiopharm Theranostics Announces Positive Phase 2b Trial Resultsof RAD 101 for Diagnosis of Brain Metastases radiopharmtheranostics.com ↗ |
| 2026-07-23 | Radiopharm Theranostics, Ltd | Results RAD Presentation July 2026 radiopharmtheranostics.com ↗
First two programs reporting strong clinical data. |
| 2025-10-20 | Radiopharm Theranostics, Ltd | Results Radiopharm Theranostics Provides Positive Clinical Updates Across Four Programs radiopharmtheranostics.com ↗
Data from the first three patients show significant and selective tumor uptake in brain metastases. |
| 2025-02-10 | Radiopharm Theranostics, Ltd | Results Clinical trial data shows RAD 101 detects Brain Metastases radiopharmtheranostics.com ↗
New clinical trial data highlights RAD 101 (18F-Pivalate) successfully detects Brain Metastases |
All press releases naming this drug 5 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-07-23 | Radiopharm Theranostics, Ltd | Radiopharm Theranostics Announces Positive Phase 2b Trial Resultsof RAD 101 for Diagnosis of Brain Metastases radiopharmtheranostics.com ↗ |
| 2026-07-23 | Radiopharm Theranostics, Ltd | RAD Presentation July 2026 radiopharmtheranostics.com ↗ |
| 2025-10-20 | Radiopharm Theranostics, Ltd | Radiopharm Theranostics Provides Positive Clinical Updates Across Four Programs radiopharmtheranostics.com ↗ |
| 2025-02-10 | Radiopharm Theranostics, Ltd | Clinical trial data shows RAD 101 detects Brain Metastases radiopharmtheranostics.com ↗ |
| 2024-10-21 | Radiopharm Theranostics, Ltd | BAMF Health to manufacture & dose for RAD101 Phase 2b trial radiopharmtheranostics.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RAD101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06777433 ↗ |
| Modality | Diagnostic / imaging agent | “to establish the imaging performance of RAD101 PET” NCT06777433 ↗ |
| Route | Intravenous | “through a slow intravenous (IV) bolus injection” NCT06777433 ↗ |